Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Zingo: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Zingo - General Information

A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. [PubChem]

 

Pharmacology of Zingo

Zingo is an anesthetic agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Zingo appears to be similar to that of procaine, procainamide and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected. In contrast to the latter 3 drugs, Zingo in therapeutic doses does not produce a significant decrease in arterial pressure or in cardiac contractile force. In larger doses, lidocaine may produce circulatory depression, but the magnitude of the change is less than that found with comparable doses of procainamide.

 

Zingo for patients

Patient may experience temporary loss of sensation and motor activity, usually in the lower half of the body, following proper administration of epidural anesthesia.

The safety and effectiveness of lidocaine depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies. Standard textbooks should be consulted for specific techniques and precautions for various regional anesthetic procedures.

 

Zingo Interactions

The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.

Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.

Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential.

Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.

 

Zingo Contraindications

Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

 

Additional information about Zingo

Zingo Indication: For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks. Mechanism Of Action: Zingo stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Lidocaine Synonyms: Dilocaine; L-Caine Drug Category: Antiarrhythmic Agents; Anesthetics Drug Type: Small Molecule; Approved Other Brand Names containing Lidocaine: Dalcaine; Lidoject-1; Lidoject-2; Octocaine; Xylocaine; Xylocaine-MPF; Xylocaine-MPF with Glucose; Octocaine-50; Octocaine-100; Xylocaine Test Dose; Xylocaine 5% Spinal; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Alphacaine; Anestacon; Anestacon Jelly; Cappicaine; DermaFlex; Duncaine; Emla; Esracaine; Gravocain; Isicaina; Lanabiotic; Leostesin; Lidoderm; Lignocaine; Maricaine; Norwood Sunburn Spray; Rocephin Kit; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Viscous; Xylocard; Zilactin-L; Solarcaine; Solarcaine aloe extra burn relief cream; Solcain; Zingo; Absorption: Information derived from diverse formulations, concentrations and usages reveals that lidocaine is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent. Toxicity (Overdose): The oral LD 50 of lidocaine HCl in non-fasted female rats is 459 (346-773) mg/kg (as the salt) and 214 (159-324) mg/kg (as the salt) in fasted female rats. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest. Protein Binding: 60-80% Biotransformation: Primarily hepatic. Half Life: 109 minutes Dosage Forms of Zingo: Solution IntravenousLiquid TopicalLiquid IntravenousOintment TopicalSpray TopicalLotion TopicalSolution OralLiquid BuccalCream TopicalGel TopicalAerosol TopicalSwab TopicalJelly TopicalLiquid DentalSolution IntramuscularLiquid OralSolution TopicalJelly UrethralAerosol, metered TopicalLiquid InfiltrationSolution Infiltration Chemical IUPAC Name: 2-diethylamino-N-(2,6-dimethylphenyl)acetamide Chemical Formula: C14H22N2O Lidocaine on Wikipedia: https://en.wikipedia.org/wiki/Lidocaine Organisms Affected: Humans and other mammals